Can-Fite's Namodenoson Shows Dose-Dependent Anti-Obesity Effects, Cuts Murine Weight Gain Significantly
CANF•Peer-reviewed study shows namodenoson inhibits adipocyte proliferation and reduces murine weight gain significantly in a dose-dependent manner after four weeks of daily oral dosing. Broad patent portfolio and established safety profile position namodenoson for potential obesity therapy in a market projected to reach $60.5 billion by 2030.
1. Publication Demonstrates Anti-Obesity Activity
In vitro assays on 3T3-L1 adipocytes revealed dose-dependent inhibition of lipid droplet accumulation and cell proliferation, while four weeks of daily oral dosing in a high-fat diet murine model produced a statistically significant reduction in weight gain compared to placebo.
2. Mechanistic Insights
Namodenoson modulated adipogenesis and inflammatory pathways by upregulating adiponectin and suppressing PI3K, NF-κB, Akt and Wnt/β-catenin signaling, suggesting a multi-pathway mechanism underlying its anti-obesity effects.
3. Market and Development Implications
This evidence extends namodenoson's profile beyond liver and inflammatory diseases into the obesity segment, a market forecast to reach $60.5 billion by 2030 at a 22% CAGR, bolstered by the drug's favorable safety record and broad patent estate.
4. Clinical Pipeline and Next Steps
Namodenoson is currently in a Phase IIb trial for MASH and a Phase III trial for hepatocellular carcinoma, with further exploration of obesity indications pending clinical initiation and regulatory evaluation.
